CBIO Stock Reverses Course, Despite Hemophilia Study Success

Catalyst Biosciences shares were on fire prior to today

Digital Content Manager
Jul 8, 2019 at 10:29 AM
facebook X logo linkedin


The shares of Catalyst Biosciences Inc (NASDAQ:CBIO) were up in early market trading, after the drugmaker announced its treatment, MarzAA, successfully reduced bleeding episodes in patients with hemophilia during a mid-stage study. However, unlike sector peer Sangamo Therapeutics (SGMO), CBIO stock quickly reversed course to trade lower. The stock is down 6.3% at $8.72, just coming off Friday's three-month highs. 

In fact, the equity was enjoying a serious surge on the charts before today. Since bottoming out at a year-to-date low of $6.92 in early June, CBIO not only managed to string together four consecutive weekly wins, but just racked up a 26.3% weekly surge -- the biggest since an early April spike. Now, the stock is trading back below its 200-day moving average -- a trendline CBIO toppled on Friday. 

While analysts are pretty quiet on the biopharma name, all four in coverage give it a "buy" or better rating. Plus, the consensus 12-month price target is more than three times CBIO's current price, at $27.25 -- a region the area hasn't touched since before a massive June 2018 bear gap

While shorts are jumping off the bearish bandwagon in droves, down 21.6% in the last two reporting periods, the 920,000 shares sold short still represent almost a quarter of the stock's float. Plus, it would take six days to cover these pessimistic positions, at the security's average pace of trading.

What's more, the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.14 is at the bottom of its annual range, meaning short-term option players haven't been more call-heavy during the past 12 months. 

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI